U.S. Software Stock News

NYSE:ZWS
NYSE:ZWSBuilding

Does Zurn Elkay’s Expanded US$550 Million Revolver Reshape the Bull Case for ZWS?

On February 19, 2026, Zurn Elkay Water Solutions’ subsidiaries entered into Amendment No. 3 to their first lien credit agreement, refinancing existing revolving borrowings, expanding the revolving credit facility from US$200,000,000 to US$550,000,000, and extending the facility’s maturity to February 19, 2031. The revised agreement, which ties interest margins and fees to net first lien leverage and boosts remaining borrowing capacity to US$540,100,000, materially increases Zurn Elkay’s...
NasdaqGS:SFM
NasdaqGS:SFMConsumer Retailing

Sprouts Leadership Shift Targets Customer Engagement As Valuation Gap Persists

Sprouts Farmers Market appointed Amanda Rassi as its first chief customer officer and Don Clark as chief merchandising officer. The leadership changes signal a fresh focus on customer engagement, personalization and merchandising across the business. Investors are watching how the new C-suite structure will influence shopper loyalty and sales trends. Sprouts Farmers Market (NasdaqGS: SFM) is entering this leadership reset with a share price of $73.73. The stock has seen a 9.0% return over...
NYSE:ALSN
NYSE:ALSNMachinery

Allison Transmission Holdings (ALSN) Margin Compression Challenges Long‑Term Profitability Narrative

Allison Transmission Holdings (ALSN) closed out FY 2025 with Q4 revenue of US$737 million and basic EPS of US$1.19, alongside net income of US$99 million that sets the tone for how investors read the full year. The company has seen quarterly revenue move from US$824 million in Q3 2024 to US$814 million in Q2 2025, US$693 million in Q3 2025 and then US$737 million in Q4 2025. Basic EPS shifted from US$2.30 to US$2.32, US$1.63 and US$1.19 over the same stretch, giving a clear read on how top...
NasdaqGM:NVTS
NasdaqGM:NVTSSemiconductor

Navitas Semiconductor (NVTS) Revenue Drop To US$7.3 Million Tests Bullish Growth Narrative

Navitas Semiconductor (NVTS) has just wrapped up FY 2025 with fourth quarter revenue of US$7.3 million and a basic EPS loss of US$0.14, while trailing 12 month figures show revenue of US$45.9 million and a full year EPS loss of US$0.57. Over the past few quarters, the company has seen revenue move from US$21.7 million with EPS of US$0.10 loss in Q3 2024 to US$10.1 million and EPS of US$0.09 loss in Q3 2025, alongside net income losses ranging from US$18.7 million to US$31.8 million in recent...
NasdaqGS:MMSI
NasdaqGS:MMSIMedical Equipment

Merit Medical Systems (MMSI) Premium P/E Faces Slower 6.8% EPS Growth Narrative Test

Merit Medical Systems (MMSI) closed FY 2025 with fourth quarter revenue of US$393.9 million and basic EPS of US$0.64, supported by trailing twelve month revenue of US$1.5 billion and EPS of US$2.17 that frame the full year picture. Over the past six reported quarters, the company has seen quarterly revenue move from US$339.8 million in Q3 2024 to US$393.9 million in Q4 2025, while quarterly basic EPS ranged between US$0.47 and US$0.64 across that stretch. With trailing net profit margin at...
NYSE:AES
NYSE:AESRenewable Energy

Did AES’ 20‑Year Google Data Center Deal Just Shift AES’ (AES) Investment Narrative?

The AES Corporation recently announced it has entered 20‑year Power Purchase Agreements with Google to develop and own co‑located energy generation for a new data center in Wilbarger County, Texas, including securing land, grid interconnection, and building shared electricity infrastructure. This long-duration partnership deepens AES’s role as an energy provider to hyperscale data centers, highlighting its capabilities in delivering tailored, on-site power and long-term energy management...
NYSE:ZETA
NYSE:ZETASoftware

Zeta Global Holdings (ZETA) Returns To Quarterly Profit, Testing Longstanding Skepticism On Profitability Path

Zeta Global Holdings (ZETA) closed FY 2025 with Q4 revenue of US$394.6 million and basic EPS of US$0.03, alongside net income of US$6.5 million, setting a clear marker after a year that started in the red. Over the past four quarters, the company reported revenue increasing from US$314.7 million in Q4 2024 to US$394.6 million in Q4 2025, while basic EPS moved from US$0.07 to US$0.03. Trailing twelve month EPS stood at a loss of US$0.13, so the latest quarterly profit comes against a year that...
NYSE:MHO
NYSE:MHOConsumer Durables

Is It Too Late To Consider M/I Homes (MHO) After Its Strong Multi Year Rally?

If you are wondering whether M/I Homes is still good value after a strong multi year run, this article walks through how its current share price stacks up against several valuation measures. The stock closed at US$140.40 recently, with returns of 4.8% over 30 days, 9.8% year to date and 17.9% over 1 year. The 3 year return sits at a very large 138.7%, and the 5 year return at 180.7%. Recent coverage of M/I Homes has focused on its position within the U.S. homebuilding sector and how...
NYSE:NX
NYSE:NXBuilding

How Margin Deterioration Amid Revenue Growth At Quanex Building Products (NX) Has Changed Its Investment Story

Over the past few years, Quanex Building Products has experienced a significant drop in operating margin, earnings per share, and return on invested capital despite continuing to grow its revenue base. This combination of rising costs and weaker profitability on a per‑share and invested‑capital basis points to mounting operational pressures and fewer attractive growth opportunities within the business. Next, we’ll examine how this sustained margin deterioration challenges Quanex’s earlier...
NYSE:ITW
NYSE:ITWMachinery

Illinois Tool Works Credit Facility Refreshes Liquidity As Valuation Runs Rich

Illinois Tool Works (NYSE:ITW) has entered into a new US$3.0b five year revolving credit facility. The agreement replaces the company’s previous revolving credit facility more than a year before its scheduled expiry. The facility includes multi currency and rate options and can be increased to up to US$5b, subject to conditions. Illinois Tool Works, a diversified industrial manufacturer serving multiple end markets, now has a refreshed liquidity backstop that can support its ongoing...
NYSE:HPQ
NYSE:HPQTech

HPQ Q1 2026 Margin Compression Reinforces Bear Narratives On Profitability

HP (HPQ) has opened Q1 2026 with revenue of US$14.4b and basic EPS of US$0.59, putting fresh numbers on the table for investors tracking how the story is evolving. The company has seen quarterly revenue move from US$14.1b in Q4 2024 to US$13.5b in Q1 2025 and US$14.4b in Q1 2026, while basic EPS has shifted from US$0.94 to US$0.60 and now US$0.59, setting a clear earnings run rate for the latest quarter. With these results in hand, the focus now turns to what they signal about HP's margin...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

US Stock Market Today: S&P 500 Futures Dip As Rate Cut Expectations Cool

The Morning Bull - US Market Morning Update Thursday, Feb, 26 2026 US stock futures are mixed this morning, with S&P 500 contracts slightly softer while Nasdaq 100 and Dow futures hold near flat, as investors weigh stronger global growth signals against interest rate worries. Taiwan just reported a record current account surplus of about US$69.9b, powered by a US$63.6b goods trade surplus tied to AI and electronics exports, which underlines how demand for chips and hardware is feeding into...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Is Shoals Technologies Group (SHLS) Pricing Look Reasonable After The Recent Share Price Slump

If you are looking at Shoals Technologies Group and wondering whether the current share price reflects its true value, this article will walk you through what the numbers are saying in plain terms. The stock last closed at US$6.85, with returns of a 36.2% decline over 7 days, a 26.1% decline over 30 days, a 24.6% decline year to date, a 76.8% gain over 1 year, a 72.8% decline over 3 years and a 79.8% decline over 5 years, which gives a mixed picture of recent and longer term...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Iovance Lifileucel Data Points To Broader Solid Tumor Opportunity

Iovance Biotherapeutics (NasdaqGM:IOVA) reported encouraging clinical trial data for lifileucel in patients with advanced sarcoma. The company plans to initiate a registrational trial and pursue accelerated FDA approval for lifileucel in this sarcoma setting. Iovance also received FDA Fast Track designation for lifileucel in non-small cell lung cancer. Iovance Biotherapeutics focuses on developing tumor infiltrating lymphocyte (TIL) therapies for difficult-to-treat cancers. The new sarcoma...
NasdaqGS:CLNE
NasdaqGS:CLNEOil and Gas

Clean Energy Fuels (CLNE) Loss Deepens To US$0.20 EPS Challenging Turnaround Narratives

Clean Energy Fuels (CLNE) has wrapped up FY 2025 with Q4 revenue of US$112.3 million and a basic EPS loss of US$0.20, while the trailing twelve months show revenue of US$424.8 million and a basic EPS loss of US$1.01, keeping the story firmly in loss-making territory. Over recent quarters the company has seen quarterly revenue move in a tight band between US$102.6 million and US$112.3 million, as quarterly basic EPS losses ranged from US$0.09 to US$0.60. This has left investors focused on how...
NYSE:CRK
NYSE:CRKOil and Gas

Dallas Salazar’s New Family Office Renews Focus On Comstock Resources

Early Comstock Resources investor Dallas C. Salazar has launched a new family office, Two Texas Presidents, focused on energy sector investments. Salazar has been involved in prior acquisition events at Comstock Resources, which brought him significant gains. The new family office keeps attention on Comstock Resources' history with high profile energy investors such as Salazar. For investors watching Comstock Resources (NYSE:CRK), the launch of Two Texas Presidents adds context around the...
NYSE:TFC
NYSE:TFCBanks

Truist Bitcoin ETFs And Open Banking Move Tie Into Undervalued Shares

Truist Financial (NYSE:TFC) is offering clients access to SEC registered spot Bitcoin ETFs through Truist Investment Services Inc. The bank has also launched open banking connectivity in partnership with Mastercard, giving clients new ways to link and manage financial data. These moves expand Truist Wealth's product shelf and introduce new digital tools for clients who want broader choice and more control. For a large US regional bank focused on retail, wealth, and commercial banking, this...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...
NasdaqGS:CSGP
NasdaqGS:CSGPReal Estate

CoStar Group (CSGP) Margin Squeeze Challenges Bullish Earnings Narratives After FY 2025 Results

CoStar Group FY 2025 results: revenue climbs while profitability tightens CoStar Group (CSGP) has wrapped up FY 2025 with Q4 revenue of US$900 million and basic EPS of US$0.11, setting the tone for a year where top line growth led the story while profitability stayed slim. Over the past six quarters, revenue has moved from US$692.6 million in Q3 2024 to US$900 million in Q4 2025, while quarterly basic EPS has swung between a loss of US$0.07 in Q3 2025 and a high of US$0.15 in Q4 2024. This...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis Pharmaceuticals Q4 Loss Of US$229 Million Tests Bullish Profitability Narrative

Ionis Pharmaceuticals FY 2025 earnings snapshot Ionis Pharmaceuticals (IONS) closed FY 2025 with fourth quarter revenue of US$203 million and a basic EPS loss of US$1.41, alongside a trailing twelve month revenue base of US$944 million and a TTM basic EPS loss of US$2.38. Over the past year, quarterly revenue has moved between US$131.6 million and US$452.0 million, while basic EPS swung from a profit of US$0.78 in Q2 2025 to losses of US$0.93 in Q1 and US$0.80 in Q3. This sets up a results...
NYSE:MIR
NYSE:MIRElectronic

New Global Tariffs Test Mirion Technologies Margins And Valuation Outlook

Mirion Technologies (NYSE:MIR) is facing material trade policy uncertainty after the US administration imposed new 15% global tariffs under the Trade Act of 1974. The tariffs follow a recent Supreme Court ruling and are being implemented abruptly, affecting companies with international supply chains. For Mirion, the policy shift raises questions around cost structure, operational planning, and future financial results. Mirion Technologies, trading at $21.49, now sits at the center of a...
NYSE:SEM
NYSE:SEMHealthcare

Select Medical (SEM) Issues 2026 Outlook After Margin Pressure: Is Its Earnings Power Repositioning?

In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure. On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees...
NYSE:XPRO
NYSE:XPROEnergy Services

Expro Buyback And North Africa Contract Reframe Valuation And Cash Flow

Expro Group Holdings (NYSE:XPRO) has authorized a new $100 million share repurchase program. The company has secured a major multi-year contract in North Africa with an initial four-year term. Recent earnings included higher margins and free cash flow, alongside softer revenue in certain regions. Expro Group, a global energy services provider listed on the NYSE as XPRO, is active across well construction, well flow management, and subsea services. The mix of a sizable buyback authorization...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Corcept Therapeutics (CORT) Margin Compression Reinforces Bearish Narrative Despite FY 2025 Revenue Strength

Corcept Therapeutics FY 2025 earnings snapshot Corcept Therapeutics (CORT) has wrapped up FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.24, alongside net income of US$25.4 million. Over the past six quarters, the company has seen revenue move from US$181.9 million in Q4 2024 to a range between US$157.2 million and US$207.6 million per quarter, while basic EPS has ranged between US$0.19 and US$0.45. With a trailing 12 month net profit margin of 13.1% compared to 20.7% a...